{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:50:23Z","timestamp":1791528623775,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09721-4","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:07:06Z","timestamp":1778296026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation"],"prefix":"10.1186","volume":"27","author":[{"given":"Mayank","family":"Gangwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevinkumar","family":"Kansagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-5097","authenticated-orcid":false,"given":"Aparna","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"2","key":"9721_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/0929867013373778","volume":"8","author":"AS Mehanna","year":"2001","unstructured":"Mehanna AS. Sickle cell anemia and antisickling agents then and now. Curr Med Chem. 2001;8(2):79\u201388.","journal-title":"Curr Med Chem"},{"key":"9721_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","volume":"14","author":"P Sundd","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol Mech Dis. 2019;14:263\u201392.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"9721_CR3","doi-asserted-by":"crossref","unstructured":"Cabrera L, Mar\u00edn-Sanchis A, Mart\u00ednez-Garc\u00eda JJ, Solves P, Balanza-Garc\u00eda R. The current role of hydroxyurea in the treatment of sickle cell disease. J Clin Med [Internet]. 2024 Oct 25 [cited 2026 Apr 6];13(21):6404. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11546997\/.","DOI":"10.3390\/jcm13216404"},{"key":"9721_CR4","unstructured":"Kavazarakis E, Vrachinis G, Kourakli A, et al. Chronic hydroxyurea therapy in children with sickle cell anemia. J Clin Med [Internet]. 2025 Dec 4 [cited 2026 Apr 6];14(2):[approx. 20 p.]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12692880\/."},{"key":"9721_CR5","doi-asserted-by":"crossref","unstructured":"Matte A, Zorzi F, Mazzi F, Federti E, Olivieri O, De Franceschi L. New therapeutic options for the treatment of sickle cell disease. Mediterr J Hematol Infect Dis. 2019;11(1):e2019002.","DOI":"10.4084\/mjhid.2019.002"},{"issue":"11","key":"9721_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40265-022-01744-w","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Desidustat: first approval. Drugs. 2022;82(11):1207\u201312.","journal-title":"Drugs"},{"key":"9721_CR7","doi-asserted-by":"publisher","first-page":"14462","DOI":"10.1021\/acs.analchem.1c02923","volume":"93","author":"LK Janssens","year":"2021","unstructured":"Janssens LK, Stove CP. Sensing an oxygen sensor: development and application of activity-based assays directly monitoring HIF heterodimerization. Anal Chem. 2021;93:14462\u201370.","journal-title":"Anal Chem"},{"key":"9721_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40262-017-0551-3","volume":"57","author":"KA Kansagra","year":"2018","unstructured":"Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, et al. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin Pharmacokinet. 2018;57:87\u2013102.","journal-title":"Clin Pharmacokinet"},{"key":"9721_CR9","doi-asserted-by":"crossref","unstructured":"Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, et al., Trial Investigators, 2019. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019;49(6);470\u2013478.","DOI":"10.1159\/000500232"},{"issue":"11","key":"9721_CR10","doi-asserted-by":"publisher","first-page":"1265313","DOI":"10.3389\/fpubh.2023.1265313","volume":"21","author":"S Chattoo","year":"2023","unstructured":"Chattoo S, Jain D, Nashine N, Singh R. A social profile of deaths related to sickle cell disease in India: a case for an ethical policy response. Front Public Health. 2023;21(11):1265313.","journal-title":"Front Public Health"},{"key":"9721_CR11","doi-asserted-by":"crossref","unstructured":"Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U, et al. Study Investigator Group. Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D). Am J Nephrol. 2022;53(5):343\u201351.","DOI":"10.1159\/000523949"},{"issue":"4","key":"9721_CR12","doi-asserted-by":"publisher","first-page":"1459425","DOI":"10.3389\/fneph.2024.1459425","volume":"22","author":"A Joharapurkar","year":"2024","unstructured":"Joharapurkar A, Pandya V, Patel H, Jain M, Desai R. Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia. Front Nephrol. 2024;22(4):1459425.","journal-title":"Front Nephrol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09721-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09721-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:51:10Z","timestamp":1783043470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09721-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9721"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09721-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6911159\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial complies with approved protocol, ICH-GCP guidelines, Indian GCP, New Drugs and Clinical Trial Rules, 2019, and all applicable regulatory requirements. The study commenced after receiving approval from a CDSCO-registered Ethics Committee (EC) for protocol, informed consent form (ICF), and participant information sheet. The study is approved by CDSCO, CT NOC No. is CT\/SND\/27\/2023, protocol number DESI.23.001, registered on 12 June 2023. All participants will provide written informed consent before any trial-related procedures. For illiterate participants, the consent process will involve a verbal explanation in a language understood by the participant, a thumb impression, and the signature of an impartial witness. Participants will receive a copy of the signed consent form. Medical records may be accessed by authorized sponsor representatives, EC members, and regulatory inspectors for monitoring and audit purposes. Amendments to the consent documents will require EC approval and re-consent of affected participants, as applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"This is the study protocol manuscript and no patient data is submitted as a part of this document. Consent for publication of results is being obtained at the time of obtaining informed consent during the enrollment process. The patient information material and informed consent form will be available from ICMR and Zydus Lifesciences Limited upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The following individuals are employed by and have affiliations with the organizations listed: MG, GK, SR, SK, and AM: Indian Council of Medical Research (ICMR), co-funder of the study. DP, KK, and SS: Zydus Lifesciences Limited, co-funder of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"465"}}